15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Exagen Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $8.00 to $10.00, so the covering firms are broadly aligned. The average target of $8.86 sits 102% above the current $4.39. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.15 next quarter toward $-0.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Exagen Inc.
As of Jul, 7 of 7 firms rate XGN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
XGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.15
Range $-0.15 – $-0.15 · 1 analysts · -52% YoY
Next period, 1 analysts expect Exagen Inc to earn $-0.15 a share (range $-0.15 – $-0.15), versus $-0.31 a year earlier. Full-year consensus is $-0.67, growing to $-0.43 the year after.
REVENUE · NEXT QUARTER
$18.4M
Range $18.0M – $19.0M · 1 analysts · +7% YoY
Revenue is expected to reach $18.4M (range $18.0M – $19.0M), +6.8% year-over-year. Full-year consensus is $71.7M, rising to $79.4M next year.
Top analysts covering Exagen Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XGN.
#1
Ross Osborn
Cantor Fitzgerald · Rank #139
Buy
$10.00+127.8% to target
Overall win rate
34%
+ Follow
#2
KM
Kyle Mikson
Canaccord Genuity · Rank #192
Buy
$8.00+82.2% to target
Overall win rate
35%
+ Follow
#3
Paul Knight
Keybanc · Rank #296
Buy
$10.00+127.8% to target
Overall win rate
32%
+ Follow
#4
Mark Massaro
BTIG
Buy
$8.00+82.2% to target
Coverage
—
+ Follow
#5
AS
Anderson Schock
B. Riley Securities
Buy
$8.00+82.2% to target
Coverage
—
+ Follow
XGN stock forecast FAQ
What is XGN's average 12-month price target?+
The 7 analysts with a live target average $8.86 for Exagen Inc over the next 12 months, ranging from a $10.00 high to a $8.00 low.
Is XGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for XGN?+
The Street-high target is $10.00 (Craig-Hallum), and the Street-low is $8.00 (Roth Capital). The average of all 7 active targets is $8.86.
How many Wall Street analysts cover XGN?+
7 analysts have an active rating on Exagen Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering XGN?+
Among analysts who currently cover XGN, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #139). Their current call is Buy with a $10.00 target.
What is Exagen Inc's projected EPS for next quarter?+
The consensus estimate is $-0.15 per share (range $-0.15 – $-0.15) across 1 analysts. Full-year EPS is projected at $-0.67, rising to $-0.43 the following year.
How much revenue is Exagen Inc expected to report next quarter?+
Consensus revenue is $18.4M (range $18.0M – $19.0M). Full-year revenue is projected at $71.7M, growing to $79.4M next year.
Have analysts been upgrading or downgrading XGN lately?+
As of Jul, 7 of 7 firms rate XGN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
